First Manhattan

First Manhattan’s Neurogene NGNE Stock Holding History

First Manhattan’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-10,006	Closed	-$2.81M	–	1461
2015 Q3	$2.81M	Buy	+10,006	New	+$2.31M	0.02%	301

Other funds holding NGNE

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

First Manhattan's NGNE Position: Q4 2015 in Review

First Manhattan sold out of Neurogene (NGNE) in Q4 2015, closing a stake of 10,006 shares — an estimated $2.81M sold.

First Manhattan first reported a position in NGNE in Q3 2015 and held it in 1 quarter. The position peaked at $2.81M in Q3 2015. 39 funds tracked by Wall St. Rank hold NGNE as of Q4 2015.

First Manhattan reported no remaining Neurogene position as of Q4 2015 after selling out during the quarter.
First Manhattan sold 10,006 Neurogene shares in Q4 2015, an estimated $2.81M.
First Manhattan first reported a position in Neurogene in Q3 2015 and held it in 1 quarter.
First Manhattan's Neurogene position peaked at $2.81M in Q3 2015.
39 funds tracked by Wall St. Rank held Neurogene as of Q4 2015.

Based on First Manhattan's 13F filing for Q4 2015, filed 20 Jan 2016.